MedTrace Logo

Phase III Randomized Study of High Vs Standard Dose of Interferon Alfa for Chronic Hepatitis C

NCT00004804 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2005-06-24

No results posted yet for this study

Summary

OBJECTIVES: I. Determine whether the initial response to interferon alfa (IFN-A) can be increased by starting at a dose of 5 MU three times a week in patients with chronic hepatitis C.

II. Determine whether patients who had normalized alanine aminotransferase (ALT) levels can maintain normal ALT during stepwise dose reduction from 5 MU to 3 MU to 1.5 MU.

Conditions

  • Hepatitis C

Interventions

DRUG

interferon alfa

Sponsors & Collaborators

  • Tulane University School of Medicine

    collaborator OTHER

  • National Center for Research Resources (NCRR)

    lead NIH

Principal Investigators

  • Anna S. F. Lok · Tulane University School of Medicine

Study Design

Purpose
TREATMENT

Eligibility

Min Age
0 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1993-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004804 on ClinicalTrials.gov